Shots: The expanded program offers access to any branded BMS’s therapies for free, including its most widely prescribed therapies and those prescribed via telehealth services Patients can reach to BMS’ patient support programs by calling it on (800) 721-8909 or by visiting BMS.com. The program provides immediate access for patients who have lost their employment […]Read More
Shots: The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19 Under the amended collaboration, Vir will be responsible for the development of selected DCs and the […]Read More
Shots: The companies collaborate to develop and commercialize BPN14770 for AD, Fragile X syndrome and other indications marked by cognitive and memory deficits. Shionogi has increased its equity investment in Tetra to 50% and has an option to acquire the remaining equity if certain conditions are met based on the results of P-II PICASSO AD […]Read More
Shots: Fibrocor to receive upfront, option exercise fee, milestones and royalties on sales of the product. Galapagos to receive an exclusive option to in-license up to 4 targets, out of which two reached the lead optimization stage Galapagos takes an equity stake in Fibrocor and will get an exclusive global right to commercialize the developed […]Read More
Shots: Athenex to receive $30M up front, ~$170M milestones and royalties on sales of licensed products in China, Hong Kong and Macao. Xiangxue to get exclusive license to develop & commercialize Athenex’s oral Paclitaxel, oral Irinotecan and Tirbanibulin ointment for the treatment of actinic keratosis (AK) in licensed territories The collaboration represents the expansion of […]Read More
Shots: As per the first agreement, Ardelyx to receive $10M for research and is eligible to receive ~10.5M upfront and up to $500M as development & commercialization milestone and will execute research in collaboration with Kyowa Kirin for only two targets Following the end of the research period, Kyowa Kirin to get an option to […]Read More
Shots: Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in to such genome editing tools for the development of gene-edited alpha-beta T cell therapies In May’2015, Editas and Juno entered into an exclusive collaboration to […]Read More
Shots: Leo Pharma(Leo) will select the targets and MorphoSys will recognize lead molecules using peptide technology platform. Leo Pharma will either develop the lead molecules or use them to design the other drug candidates Leo will have exclusive, worldwide rights and take care of the development and commercialization of any drugs developed in dermatology. MorphoSys […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
